Related Experiment Video

Updated: May 16, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth

Lori N Griner1, Kathy L McGraw, Joseph O Johnson

  • 1Cancer Biology Ph.D. Program, University of South Florida, H. Lee Moffitt Cancer Center, Tampa, FL, USA.

British Journal of Haematology
|November 20, 2012
PubMed

Insights

Aberrant Janus kinase 2 (JAK2) signaling drives myeloproliferative neoplasms (MPNs). Targeting cholesterol-rich lipid rafts with statins inhibits JAK2-V617F signaling and cell growth, offering a potential MPN therapy.

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Aberrant Janus kinase 2 (JAK2) signaling is a key driver in myeloproliferative neoplasms (MPNs).
  • Current JAK2 inhibitors do not eliminate neoplastic cells, necessitating novel therapeutic strategies.
  • Emerging evidence suggests cellular cholesterol's role in JAK2 activation and MPN development.

Purpose of the Study:

  • To investigate the localization and dependency of the MPN-associated JAK2-V617F kinase on lipid rafts.
  • To evaluate the therapeutic potential of targeting lipid rafts and cholesterol metabolism in MPNs.

Main Methods:

  • Immunofluorescence microscopy to determine JAK2-V617F localization in lipid rafts.
  • Treatment with lipid raft-disrupting agents and statins (HMG-CoA reductase inhibitors).
  • Assessment of cell apoptosis, proliferation, and erythroid colony formation in MPN patient-derived cells and healthy controls.

Main Results:

  • The JAK2-V617F kinase was found to localize within lipid rafts.
  • Disruption of lipid rafts inhibited JAK2-V617F signaling.
  • Statins induced apoptosis and inhibited JAK2-V617F-dependent cell growth, with MPN cells showing increased sensitivity.
  • Statin treatment reduced erythropoietin-independent erythroid colony formation in MPN patient cells.

Conclusions:

  • JAK2-V617F signaling in MPNs is dependent on lipid raft integrity.
  • Statins demonstrate therapeutic potential by targeting cholesterol-dependent JAK2 signaling pathways in MPNs.
  • Targeting lipid rafts represents a promising new therapeutic avenue for myeloproliferative neoplasms.

More Related Videos

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells07:12

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...